The COVID-19 drug of AstraZeneca (NASDAQ: AZN) and Oxford University will be assessed after the firm has commenced a study to check the protection and potency of the vaccine candidate in children for the first time. The drug candidate of AstraZeneca and Oxford university which is referred as the ChAdOx1 nCoV-19 drug is to be assessed in children and checked whether the drug is secure for the age group between 6 and 17.
Oxford University disclosed that nearly 300 participants have enrolled themselves to help Oxford and AstraZeneca to check the immunity of their drug. Drug administration is scheduled to take place this month. The two-dose Oxford/AstraZeneca drug has been welcomed as a 'drug for the world' because it is less expensive and simpler to deliver than some competitors.
It has been disclosed that nearly 240 children will get the drug shot this month and the remaining 60 children will get the control meningitis shot. AstraZeneca is planning to produce the 3 million shots of drug this year and is planning to generate 200 million doses each month by April.
In UK other than Pfizer/BioNTech SE, and Moderna Inc’s drug, Oxford/AstraZeneca is the third one that has received the authorization to be injected in adults to prevent the spread of the virus.
The chief examiner on the Oxford drug study commented that there is a lesser number of children who got COVID and has not developed any infection, so it is very important to check the safety and potency of the drug in them and this inoculation is also useful for some children.
These new studies will increase the efficiency of Oxford University to stop the spread of the virus in children. Previously, England’s CMO stated that the studies are being carried out to develop shots that are not dangerous for the children as well.